Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.43 -1.2%	$3.34	$2.71 ▼ $4.73	$664.60M	1.23	965,340 shs	1.02 million shs
ANAB AnaptysBio	$23.17 -0.9%	$21.29	$12.21 ▼ $41.31	$687.21M	-0.26	638,189 shs	454,361 shs
DAWN Day One Biopharmaceuticals	$6.32 -1.4%	$6.84	$6.08 ▼ $16.76	$649.73M	-1.3	1.13 million shs	1.50 million shs
IPHA Innate Pharma	$1.80 -5.3%	$2.09	$1.29 ▼ $3.51	$175.13M	0.26	186,497 shs	9,046 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.15%	-2.83%	+8.20%	+4.57%	+13.95%
ANAB AnaptysBio	-0.94%	-0.64%	+11.34%	+35.66%	+1.22%
DAWN Day One Biopharmaceuticals	-1.40%	-5.25%	+0.48%	-23.21%	-52.80%
IPHA Innate Pharma	-5.26%	-5.01%	-15.89%	-11.76%	-10.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.2864 of 5 stars	3.5	0.0	3.2	2.5	0.6
ANAB AnaptysBio	2.0269 of 5 stars	3.4	0.0	3.5	1.7	0.6
DAWN Day One Biopharmaceuticals	1.6712 of 5 stars	3.6	0.0	2.3	2.5	0.0
IPHA Innate Pharma	3.06 of 5 stars	3.8	5.0	2.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	60.35% Upside
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	82.89% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	383.73% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	511.11% Upside

Current Analyst Ratings Breakdown

Latest IPHA, ABUS, ANAB, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00
4/3/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/28/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.50

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	106.47	N/A	N/A	$0.51 per share	6.73
ANAB AnaptysBio	$91.28M	7.46	N/A	N/A	$2.33 per share	9.94
DAWN Day One Biopharmaceuticals	$131.16M	4.88	N/A	N/A	$4.99 per share	1.27
IPHA Innate Pharma	$21.77M	7.62	N/A	N/A	$0.11 per share	16.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.71	N/A	N/A	N/A	-42.66%	-14.98%	-13.04%	7/8/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest IPHA, ABUS, ANAB, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
ANAB AnaptysBio	N/A	8.25	8.25
DAWN Day One Biopharmaceuticals	N/A	10.62	10.55
IPHA Innate Pharma	2.52	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ANAB AnaptysBio	N/A
DAWN Day One Biopharmaceuticals	87.95%
IPHA Innate Pharma	0.16%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ANAB AnaptysBio	33.50%
DAWN Day One Biopharmaceuticals	6.20%
IPHA Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	95.08 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable

IPHA, ABUS, ANAB, and DAWN Headlines

Recent News About These Companies

Innate Pharma (NASDAQ:IPHA) Stock Price Down 1% - Should You Sell?

June 19 at 12:50 AM | marketbeat.com

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

June 17, 2025 | businesswire.com

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

June 13, 2025 | businesswire.com

Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Update

May 30, 2025 | marketbeat.com

Innate Pharma (NASDAQ:IPHA) Shares Down 1.1% - Time to Sell?

May 28, 2025 | marketbeat.com

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025 | businesswire.com

ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody

May 23, 2025 | fiercebiotech.com

Outcome of Innate Pharma’s 2025 Annual General Meeting

May 23, 2025 | finance.yahoo.com

Outcome of Innate Pharma's 2025 Annual General Meeting

May 23, 2025 | businesswire.com

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025 | businesswire.com

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025 | businesswire.com

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025 | businesswire.com

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025 | businesswire.com

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025 | businesswire.com

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

April 30, 2025 | businesswire.com

Innate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025

April 29, 2025 | tipranks.com

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

April 29, 2025 | businesswire.com

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

April 25, 2025 | markets.businessinsider.com

Innate Pharma Announces €15M Investment by Sanofi

April 24, 2025 | businesswire.com

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

April 23, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ABUS, ANAB, and DAWN Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.43 -0.04 (-1.15%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.46 +0.03 (+1.02%)

As of 06/20/2025 05:55 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

AnaptysBio NASDAQ:ANAB

$23.17 -0.22 (-0.94%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.16 -0.01 (-0.02%)

As of 06/20/2025 06:07 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.32 -0.09 (-1.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.32 0.00 (0.00%)

As of 06/20/2025 04:20 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Innate Pharma NASDAQ:IPHA

$1.80 -0.10 (-5.26%)

Closing price 06/20/2025 03:48 PM Eastern

Extended Trading

$1.77 -0.03 (-1.61%)

As of 06/20/2025 04:48 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time